Krystal Biotech (KRYS) Operating Leases (2019 - 2026)

Krystal Biotech has disclosed Operating Leases across 8 years of filings, most recently posting $9.1 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $9.1 million, down 5.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (down 5.69% YoY), and the FY2025 annual result was $7.6 million, up 25.22% from the prior year.
• Operating Leases came in at $9.1 million for Q1 2026 at Krystal Biotech, up from $7.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.7 million in Q2 2025 to a low of $6.0 million in Q4 2024.
• The 5-year median for Operating Leases is $7.8 million (2025), against an average of $7.8 million.
• Across the five-year window, Operating Leases jumped 144.66% in 2022 and declined 25.67% in 2024, its largest moves.
• Krystal Biotech's Operating Leases stood at $7.4 million in 2022, then dropped by 10.2% to $6.6 million in 2023, then fell by 8.7% to $6.0 million in 2024, then increased by 25.22% to $7.6 million in 2025, then grew by 20.4% to $9.1 million in 2026.
• The last three Operating Leases figures came in at $9.1 million (Q1 2026), $7.6 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.